Stromacare SAS is a biotechnology startup based in Lyon, France, founded in 2020. The company is focused on pioneering tumoral stroma immuno-modulation and developing a therapeutic mAb for the treatment of cancers. With a slogan of "Stromacare is a pioneer in tumoral stroma immuno-modulation and develops a therapeutic mAb for the treatment of cancers," the company has garnered attention for targeting the tumoral stroma, which plays a key role in several solid cancers. This approach aims to be essential in numerous anticancer treatment protocols. Stromacare's dedication to innovation and impactful solutions has been recognized as it received the Beatrice Denys Foundation 2021 Prize from the Foundation for Medical Research. Despite not having available information on the last investment and investors, Stromacare's commitment to addressing critical aspects of cancer treatment positions it as a player to watch in the biotechnology and healthcare industries.
StromaCare
Stromacare is a pioneer in tumoral stroma immuno-modulation and develops a therapeutic mAb for the treatment of cancers
France
15 employees
Biotechnology, Health Care +1
General Information
France
BounceWatch is an independent company data service, not affiliated with StromaCare. To contact StromaCare, visit stroma.care.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does StromaCare compare?
A PDF of StromaCare and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting StromaCare soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
France Market
Biotechnology
About StromaCare
Business keywords: cancer treatment, immunotherapy, monoclonal antibody, tumoral stroma, solid cancers, medical research, France, Lyon, Beatrice Denys Foundation, therapeutic development
No funding data available for StromaCare yet.
StromaCare Alternatives & Competitors
View All Alternatives
Pre-clinical stage biotech company developing an antibody immunotherapy drug for cancer using an “In...
Innovation in antibody-cytokine fusion technology and monoclonal antibody-based therapies for a brig...
Targeting calcium signaling to cure auto-immune diseases
FAQ About StromaCare
Source: BounceWatch company record for StromaCare, https://bouncewatch.com/company/stromacare-sas, updated 28 November 2024. When citing, please name BounceWatch and link this page.
